Coherus BioSciences (NASDAQ:CHRS) Earns “Buy” Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $7.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 464.52% from the stock’s current price.

CHRS has been the topic of a number of other research reports. Robert W. Baird lifted their price target on Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Stock Down 3.1 %

CHRS opened at $1.24 on Thursday. The business has a fifty day simple moving average of $1.42 and a 200-day simple moving average of $1.27. The firm has a market cap of $142.86 million, a PE ratio of -15.50 and a beta of 0.82. Coherus BioSciences has a fifty-two week low of $0.66 and a fifty-two week high of $2.87.

Institutional Investors Weigh In On Coherus BioSciences

A number of institutional investors have recently bought and sold shares of the business. Systematic Financial Management LP purchased a new stake in shares of Coherus BioSciences in the third quarter worth approximately $28,000. Steph & Co. acquired a new position in Coherus BioSciences in the 4th quarter valued at approximately $34,000. Hsbc Holdings PLC lifted its position in Coherus BioSciences by 10.6% in the 2nd quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock worth $179,000 after buying an additional 9,905 shares in the last quarter. FMR LLC boosted its stake in shares of Coherus BioSciences by 21.1% during the 3rd quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 39,204 shares during the period. Finally, Rhumbline Advisers grew its holdings in shares of Coherus BioSciences by 19.5% during the 2nd quarter. Rhumbline Advisers now owns 154,904 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 25,241 shares in the last quarter. 72.82% of the stock is currently owned by institutional investors and hedge funds.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.